Maraviroc Waymade

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral formulation for oral use. It is used in combination with other antiretroviral agents to treat HIV-1 infection in adults and adolescents.

GNH USA supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is a CCR5 antagonist indicated for the treatment of HIV‑1 infection as part of combination antiretroviral therapy.

- HIV‑1 infection: reduces viral replication by blocking CCR5‑mediated entry of the virus into CD4+ T cells. - Treatment‑experienced HIV‑1 infection: provides an additional mechanism of action for patients with resistance to other drug classes. - Combination antiretroviral therapy: contributes to overall viral suppression when used with nucleoside reverse transcriptase inhibitors and protease inhibitors.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: may occur with or without vomiting. - Diarrhea: generally self‑limiting. - Fatigue: reported especially during early treatment. - Upper respiratory tract infection: includes sore throat and nasal congestion. - Cough: non‑productive and transient.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - QT interval prolongation: may predispose to cardiac arrhythmias. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but life‑threatening skin reactions. - Immune reconstitution inflammatory syndrome (IRIS): worsening of opportunistic infections. - Depression or suicidal ideation: monitor mental health status.

Before initiating therapy, clinicians should assess baseline liver function, cardiovascular status, and potential hypersensitivity.

- Monitor liver function: check transaminases periodically. - Assess cardiovascular risk: avoid in patients with known QT prolongation. - Avoid in patients with known hypersensitivity to maraviroc or any excipients. - Use caution in patients with concurrent infections: monitor for IRIS. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Maraviroc may interact with several drugs that affect CYP3A4 metabolism or P‑gp transport.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: can increase maraviroc exposure markedly. - Efavirenz: may reduce maraviroc plasma concentrations. - St. John’s wort: induces CYP3A4 and may lower maraviroc levels.

Moderate Interactions (Monitor Closely): - Azithromycin: may increase QT interval risk. - Atorvastatin: potential for increased statin exposure. - Warfarin: monitor INR as maraviroc may affect anticoagulation control.